MEDEZE Demonstrates Strong Q3/2025 Performance with THB 160 Million Net Profit Advances Toward Becoming “Thailand’s First ATMPs” and Strengthens Its Position as a Regional Medical Leader
Ms. Anchisa Lekpetch (right), Chief Accounting and Finance Officer, and Dr. Wasawat Sroithong (left), Head of Investor Relations of MEDEZE Group Public Company Limited (“MEDEZE”), jointly presented the company’s Q3/2025 operating results and business growth outlook at the “Opportunity Day” event hosted by the Stock Exchange of Thailand.
MEDEZE reported total revenue of THB 181 million and net profit of THB 30.54 million, representing a net profit margin of 17% in the third quarter. For the first nine months of 2025, the company generated total revenue of THB 587.99 million and net profit of THB 160 million, equivalent to a net profit margin of 27%. These results reflect the company’s operational efficiency, business expansion, and the accelerating growth across its services, including NK Cell Therapy, Hair Follicle Cell Bank, and Stem Cell Storage Packages, all of which continue to gain strong traction among both domestic and international clients.
The company is currently moving forward with the ATMP Sandbox project, under the supervision of the Ministry of Public Health, utilizing Bangrak Medical Center and Vachira Phuket Hospital as designated clinical trial sites. Clinical implementation is set to begin in 2026, reinforcing MEDEZE’s capability to advance innovative healthcare solutions and drive sustainable growth as it strengthens its position as a leader in the region’s medical and biotechnology sector.
IR Press Releases